PharmaBlock Sciences Nanjing Inc Class A (300725) — Net Asset Quality Index
PharmaBlock Sciences Nanjing Inc Class A (300725) has a Net Asset Quality Index of 91.7% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥7.79 Billion minus total liabilities of CN¥645.64 Million yields net assets of CN¥7.15 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check 300725 financial resilience to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
PharmaBlock Sciences Nanjing Inc Class A Net Asset Quality Index Over Time (2013–2024)
This chart shows how PharmaBlock Sciences Nanjing Inc Class A's Net Asset Quality Index has evolved across 12 annual periods from 2013 to 2024. As of September 2025, the index stands at 91.7%, representing net assets of CN¥7.15 Billion against total assets of CN¥7.79 Billion CNY. See 300725 working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for PharmaBlock Sciences Nanjing Inc Class A (2013–2024)
The table below presents the year-by-year Net Asset Quality Index for PharmaBlock Sciences Nanjing Inc Class A from 2013 to 2024, covering 12 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see market cap of PharmaBlock Sciences Nanjing Inc Class A.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 60.5% | CN¥2.99 Billion | CN¥4.94 Billion | CN¥1.95 Billion | ▲ +5.0 pp |
| 2023 | 55.5% | CN¥2.83 Billion | CN¥5.10 Billion | CN¥2.27 Billion | ▲ +0.8 pp |
| 2022 | 54.7% | CN¥2.66 Billion | CN¥4.86 Billion | CN¥2.20 Billion | ▼ -20.3 pp |
| 2021 | 74.9% | CN¥2.63 Billion | CN¥3.51 Billion | CN¥879.21 Million | ▼ -3.2 pp |
| 2020 | 78.1% | CN¥1.89 Billion | CN¥2.43 Billion | CN¥530.57 Million | ▲ +6.1 pp |
| 2019 | 72.0% | CN¥740.87 Million | CN¥1.03 Billion | CN¥288.27 Million | ▼ -6.8 pp |
| 2018 | 78.8% | CN¥599.73 Million | CN¥761.16 Million | CN¥161.43 Million | ▼ -10.0 pp |
| 2017 | 88.8% | CN¥503.59 Million | CN¥567.40 Million | CN¥63.80 Million | ▲ +3.8 pp |
| 2016 | 85.0% | CN¥254.15 Million | CN¥299.15 Million | CN¥45.00 Million | ▼ 0.0 pp |
| 2015 | 85.0% | CN¥146.56 Million | CN¥172.48 Million | CN¥25.92 Million | ▼ -0.9 pp |
| 2014 | 85.8% | CN¥87.18 Million | CN¥101.56 Million | CN¥14.38 Million | ▲ +3.4 pp |
| 2013 | 82.4% | CN¥70.16 Million | CN¥85.13 Million | CN¥14.97 Million | — |